FDA Gives Nod to Protalix's Elelyso in Gaucher Disease

Last week, the FDA increased the options available in Type I Gaucher disease by approving Elelyso (taliglucerase alfa), a recombinant version of the hydrolytic human lysosomal enzyme glucocerebrosidase. The compound was discovered by Protalix BioTherapeutics Inc., which is partnered with Pfizer Inc. on development and commercialization outside Israel.